TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

ELANIX

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: VerbalEscritório: US

Snapshot rápido

ELANIX

ST13

US500000079212480

Classe

3, 5, 9, 10, 40, 42, 44

Pedido

79212480

Registro

5634868

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

49

Atualização mais recente

12/03/2026

Classificação

Registrada

Tipo de marca

Verbal

Classes Nice

3, 5, 9, 10, 40, 42, 44

Data de depósito

07/03/2017

Data de registro

25/12/2018

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

11/07/2025

Última transação

12/03/2026

Escritório responsável

United States Patent and Trademark Office

Código da situação

709

Cadastro oficial

Principal Register

Código do desenho

4

Tipo de titular

33

Localização do titular

CH

Examinador

MAYES, LAURIE ANN

Unidade examinadora

L10

Localização atual

PUBLICATION AND ISSUE SECTION

Titulares e representantes

Titulares

Elanix Biotechnologies SA

Representantes

Lisa M. DuRoss Harness, Dickey & Pierce, PLC

Classificação técnica

Classes Nice

Classe 3Classe 5Classe 9Classe 10Classe 40Classe 42Classe 44

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 3

Cosmetic preparations, namely, preparations for cleaning, protecting and maintaining in good condition various parts of the human and animal body surface; cosmetic preparations for regeneration of the skin and mucous membranes; cosmetic preparations for personal use

Classe 5

Pharmaceutical, biological or biotechnological products for curing or treating dermatological, gynecological and orthopedic conditions namely, pharmaceutical preparations for treating dermatological, gynecological and orthopedic conditions; wound dressing containing foetal cell based/derived proteins; protein augmented surfaces for orthopaedic implants, namely, implantable scaffolds comprising living tissue primarily comprised of proteins; wound dressing containing foetal cell based/derived proteins for which the cells were cultured in conditions as to produce these proteins; protein augmented surfaces for orthopaedic implants, namely, implantable scaffolds comprising living tissue primarily comprised of proteins for orthopaedic implants; pharmaceutical, biological or biotechnological preparations, namely, specialty medicated cosmetic creams, wound dressings, implantable scaffolds comprising living tissue for enhancing therapy or maintaining tissue contour, and cell derivatives being stem cells for medical use for tissue regeneration; pharmaceutical, biological or biotechnological preparations for medical use for treatment ofgynecological illnesses; biological or biotechnological preparations for medical use for treatment of orthopedic injuries; Pharmaceutical, biological or biotechnological preparations for medical use for activating cellular functions namely, for treatment of foetal cell derived structural and adhesion proteins to alter immune responses or enhance wound healing, growth supplements for manufacturing of cell therapies

Classe 9

Software for medical applications for diagnosing and monitoring tissue healing in dermatology, orthopedics, and gynecology

Classe 10

Matrices for wound dressings in the nature of interactive wound dressings primarily composed of non-living tissue for medical use comprising artificial or organically derived but non-living scaffold materials alone or in combination with cells or cell derivatives to protect the skin and heal skin related conditions, burns, ulcers, cuts, and surgical incisions; Matrices for wound dressings in the nature of interactive wound dressings primarily composed of non-living tissue for medical use comprising artificial or organic gels or creams alone or in combination with non-living cell derivatives to protect the skin and heal skin related conditions burns, ulcers, cuts, and surgical incisions; Matrices for tissue regeneration in the nature of implantable dermatology scaffolds comprising artificial or non-living organic materials alone or in combination with cells or cell derivatives for maintaining tissue contour during tissue regeneration; Matrices in the nature of interactive wound dressings primarily composed of non-living tissue for medical use comprising artificial or non-living organic scaffold materials alone or in combination with cells or cell derivatives to protect gynecologic and urologic intimate zones and heal related conditions, lacerations, dryness, and blistering; Matrices in the nature of interactive wound dressings primarily composed of non-living tissue for medical use comprising artificial or organic gels or creams alone or in combination with cells or cell derivatives to protect gynecologic and urologic intimate zones and heal related conditions, lacerations, dryness, and blistering; Matrices for tissue regeneration in the nature of implantable gynecology scaffolds comprising artificial or non-living organic materials alone or in combination with cells or cell derivatives for maintaining tissue contour during tissue regeneration; Matrices for tissue regeneration comprising artificial or non-living organic scaffold materials alone or in combination with cells or cell derivatives to heal bone, cartilage, tendon related conditions, tendinopathies, and fractures; Matrices for tissue regeneration comprising artificial or organic gels or creams alone or in combination with cells or cell derivatives to heal bone, cartilage, tendon related conditions, tendinopathies, and fractures; Matrices for tissue regeneration in the nature of implantable orthopedic scaffolds comprising artificial or non- living organic materials alone or in combination with cells or cell derivatives for maintaining tissue contour during tissue regeneration

Classe 40

Custom manufacture of cosmetic preparations, pharmaceutical preparations and/or chemical preparations for use in industry, intermediate and finished formulations, and single constituents; Custom manufacture of biological tissue and of biotechnological products for use in research; Custom manufacture of cosmetics to order and according to customer requirements; Custom manufacture for others of biological production platforms, biotechnology production platforms for protein production, mammalian and human cells for protein production, organoid production for testing purposes, to order and according to customer requirements

Classe 42

Scientific research consulting services provided by consultants in the fields of pharmaceutical, biological, biotechnological, medical and cosmetic research, preclinical and safety assessments

Classe 44

Medical services and providing of medical information in the medical field; Medical testing and analysis for diagnostic purposes; Medical consultation services provided by consultants relating to pharmaceutical, biological, biotechnological, cosmetic and medical products

Publicações

Histórico de despachos e eventos da marca no USPTO.

49 publicações encontradas

INTR

TOTAL INVALIDATION OF REG EXT PROTECTION CREATED

11/03/2026

C71T

CANCELLED SECTION 71

11/07/2025

REM3

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED

25/12/2023

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

11/07/2022

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

11/07/2022

ECDR

TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS

11/07/2022

EWAF

TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS

11/07/2022

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

11/07/2022

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

11/07/2022

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

11/07/2022

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

26/04/2019

FICS

FINAL DISPOSITION NOTICE SENT TO IB

05/04/2019

FIMP

FINAL DISPOSITION PROCESSED

05/04/2019

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

25/03/2019

OPNX

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

05/01/2019

R.PR

REGISTERED-PRINCIPAL REGISTER

25/12/2018

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

19/12/2018

OPNR

NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

19/12/2018

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

09/10/2018

PUBO

PUBLISHED FOR OPPOSITION

09/10/2018

GPNX

NOTIFICATION PROCESSED BY IB

06/10/2018

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

19/09/2018

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

19/09/2018

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

19/09/2018

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

04/09/2018

XAEC

EXAMINER'S AMENDMENT ENTERED

31/08/2018

ALIE

ASSIGNED TO LIE

31/08/2018

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

31/08/2018

GNEA

EXAMINERS AMENDMENT E-MAILED

31/08/2018

CNEA

EXAMINERS AMENDMENT -WRITTEN

31/08/2018

NREP

NEW REPRESENTATIVE AT IB RECEIVED

07/06/2018

GNFN

NOTIFICATION OF FINAL REFUSAL EMAILED

01/03/2018

GNFR

FINAL REFUSAL E-MAILED

01/03/2018

CNFR

FINAL REFUSAL WRITTEN

01/03/2018

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

14/02/2018

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

13/02/2018

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

13/02/2018

RFNP

REFUSAL PROCESSED BY IB

01/09/2017

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

17/08/2017

RFRR

REFUSAL PROCESSED BY MPU

17/08/2017

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

01/08/2017

CNRT

NON-FINAL ACTION WRITTEN

31/07/2017

RFWR

NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW

29/07/2017

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

24/07/2017

CNRT

NON-FINAL ACTION WRITTEN

23/07/2017

MAFR

APPLICATION FILING RECEIPT MAILED

18/07/2017

DOCK

ASSIGNED TO EXAMINER

14/07/2017

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

14/07/2017

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

13/07/2017

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace ELANIX ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.